Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Genomic analysis of spermatocytic tumors demonstrates recurrent molecular alterations in cases with malignant clinical behavior

S. Gupta, LM. Sholl, Y. Yang, AO. Osunkoya, JB. Gordetsky, KM. Cornejo, K. Michalova, F. Maclean, E. Dvindenko, M. Snuderl, MS. Hirsch, WJ. Anderson, RA. Rowsey, RE. Jimenez, JC. Cheville, PM. Sadow, M. Colecchia, C. Ricci, TM. Ulbright, DM....

. 2024 ; 262 (1) : 50-60. [pub] 20231004

Language English Country England, Great Britain

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc24000140

Grant support
Department of Pathology of Brigham
Women's Hospital and Mayo Clinic

Spermatocytic tumor (ST) is a rare type of germ cell tumor that occurs exclusively in the postpubertal testis and typically affects elderly men. Most STs are benign, but rare cases exhibit aggressive clinical behavior, often in association with transition to sarcomatoid histology. Limited molecular analyses have been performed on STs; therefore, their genomic and epigenomic features remain incompletely described. Twenty-seven samples from 25 individual patients were analyzed with a combination of DNA sequencing panels, genomic methylation profiling, SNP array, isochromosome (12p) [i(12p)] FISH, and immunohistochemistry. The series included five metastasizing tumors (three with sarcomatoid transformation, one anaplastic, and one conventional) and 20 non-metastasizing tumors (14 anaplastic and six conventional). Anaplastic tumors comprised a monomorphic population of intermediate-sized neoplastic cells, as previously described. Multiomic analyses demonstrated that there were two genomic subgroups of STs: one with diploid genomes and hotspot RAS/RAF variants and the other with global ploidy shift and absence of recurrent mutations. Relative gain of chromosome 9 was a consistent finding in both subgroups. A comparison of metastasizing and non-metastasizing cases demonstrated that aggressive behavior was associated with the acquisition of pathogenic TP53 mutations and/or relative gains of 12p/i(12p). In cases with sarcomatoid transformation, TP53 mutations seem to underlie the transition to sarcomatoid histology. Genomic methylation analysis demonstrated that aggressive cases with gains of 12p cluster closer to pure seminomas than to STs without gains of 12p. In conclusion, STs include two genomic subgroups, characterized by global ploidy shifts without recurrent mutations and diploid genomes with RAS/RAF hotspot mutations, respectively. Biologic progression was associated with relative gains of 12p and TP53 mutations. The findings in STs with relative gains of 12p suggest that they may exhibit biologic characteristics akin to those seen in germ cell neoplasia in situ-related germ cell tumors rather than non-germ cell neoplasia in situ-derived STs. © 2023 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24000140
003      
CZ-PrNML
005      
20240213093000.0
007      
ta
008      
240109s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1002/path.6210 $2 doi
035    __
$a (PubMed)37792634
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Gupta, Sounak $u Department of Pathology, Mayo Clinic, Rochester, MN, USA
245    10
$a Genomic analysis of spermatocytic tumors demonstrates recurrent molecular alterations in cases with malignant clinical behavior / $c S. Gupta, LM. Sholl, Y. Yang, AO. Osunkoya, JB. Gordetsky, KM. Cornejo, K. Michalova, F. Maclean, E. Dvindenko, M. Snuderl, MS. Hirsch, WJ. Anderson, RA. Rowsey, RE. Jimenez, JC. Cheville, PM. Sadow, M. Colecchia, C. Ricci, TM. Ulbright, DM. Berney, AM. Acosta
520    9_
$a Spermatocytic tumor (ST) is a rare type of germ cell tumor that occurs exclusively in the postpubertal testis and typically affects elderly men. Most STs are benign, but rare cases exhibit aggressive clinical behavior, often in association with transition to sarcomatoid histology. Limited molecular analyses have been performed on STs; therefore, their genomic and epigenomic features remain incompletely described. Twenty-seven samples from 25 individual patients were analyzed with a combination of DNA sequencing panels, genomic methylation profiling, SNP array, isochromosome (12p) [i(12p)] FISH, and immunohistochemistry. The series included five metastasizing tumors (three with sarcomatoid transformation, one anaplastic, and one conventional) and 20 non-metastasizing tumors (14 anaplastic and six conventional). Anaplastic tumors comprised a monomorphic population of intermediate-sized neoplastic cells, as previously described. Multiomic analyses demonstrated that there were two genomic subgroups of STs: one with diploid genomes and hotspot RAS/RAF variants and the other with global ploidy shift and absence of recurrent mutations. Relative gain of chromosome 9 was a consistent finding in both subgroups. A comparison of metastasizing and non-metastasizing cases demonstrated that aggressive behavior was associated with the acquisition of pathogenic TP53 mutations and/or relative gains of 12p/i(12p). In cases with sarcomatoid transformation, TP53 mutations seem to underlie the transition to sarcomatoid histology. Genomic methylation analysis demonstrated that aggressive cases with gains of 12p cluster closer to pure seminomas than to STs without gains of 12p. In conclusion, STs include two genomic subgroups, characterized by global ploidy shifts without recurrent mutations and diploid genomes with RAS/RAF hotspot mutations, respectively. Biologic progression was associated with relative gains of 12p and TP53 mutations. The findings in STs with relative gains of 12p suggest that they may exhibit biologic characteristics akin to those seen in germ cell neoplasia in situ-related germ cell tumors rather than non-germ cell neoplasia in situ-derived STs. © 2023 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé $7 D006801
650    _2
$a senioři $7 D000368
650    12
$a seminom $x genetika $7 D018239
650    12
$a testikulární nádory $x metabolismus $7 D013736
650    12
$a germinální a embryonální nádory $x genetika $7 D009373
650    _2
$a genomika $7 D023281
650    12
$a biologické přípravky $7 D001688
650    _2
$a lidské chromozomy, pár 12 $x metabolismus $7 D002881
655    _2
$a časopisecké články $7 D016428
700    1_
$a Sholl, Lynette M $u Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
700    1_
$a Yang, Yiying $u Department of Pathology, New York University, New York, NY, USA
700    1_
$a Osunkoya, Adeboye O $u Department of Pathology, Emory University School of Medicine, Atlanta, GA, USA
700    1_
$a Gordetsky, Jennifer B $u Department of Pathology, Vanderbilt University, Nashville, TN, USA
700    1_
$a Cornejo, Kristine M $u Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
700    1_
$a Michalova, Kvetoslava $u Department of Pathology, Charles University, Plzen, Czech Republic
700    1_
$a Maclean, Fiona $u Department of Pathology, Douglass Hanly Moir Pathology, Macquarie University, Sydney, NSW, Australia
700    1_
$a Dvindenko, Eugénia $u Department of Pathology, Instituto Português de Oncologia, Lisbon, Portugal
700    1_
$a Snuderl, Matija $u Department of Pathology, New York University, New York, NY, USA $1 https://orcid.org/0000000307520917
700    1_
$a Hirsch, Michelle S $u Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
700    1_
$a Anderson, William J $u Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
700    1_
$a Rowsey, Ross A $u Department of Pathology, Mayo Clinic, Rochester, MN, USA
700    1_
$a Jimenez, Rafael E $u Department of Pathology, Mayo Clinic, Rochester, MN, USA
700    1_
$a Cheville, John C $u Department of Pathology, Mayo Clinic, Rochester, MN, USA
700    1_
$a Sadow, Peter M $u Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
700    1_
$a Colecchia, Maurizio $u Department of Pathology, Universita Vita Salute San Raffaele, Milan, Italy
700    1_
$a Ricci, Costantino $u Pathology Unit, Maggiore Hospital-AUSL Bologna, Bologna, Italy $u Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy
700    1_
$a Ulbright, Thomas M $u Department of Pathology, Indiana University, Indianapolis, IN, USA
700    1_
$a Berney, Daniel M $u Centre for Cancer Biomarkers & Biotherapeutics, Barts Cancer Institute, Queen Mary University of London, London, UK
700    1_
$a Acosta, Andres Martin $u Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA $u Department of Pathology, Indiana University, Indianapolis, IN, USA $1 https://orcid.org/0000000188176331
773    0_
$w MED00002878 $t Journal of pathology $x 1096-9896 $g Roč. 262, č. 1 (2024), s. 50-60
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37792634 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240109 $b ABA008
991    __
$a 20240213092957 $b ABA008
999    __
$a ok $b bmc $g 2049056 $s 1209834
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 262 $c 1 $d 50-60 $e 20231004 $i 1096-9896 $m Journal of pathology $n J Pathol $x MED00002878
GRA    __
$p Department of Pathology of Brigham
GRA    __
$p Women's Hospital and Mayo Clinic
LZP    __
$a Pubmed-20240109

Find record

Citation metrics

Archiving options